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Abstract
Cells of the myeloid lineage are significant targets for human immunodeficiency virus (HIV) in humans and simian
immunodeficiency virus (SIV) in monkeys. Monocytes play critical roles in innate and adaptive immunity during
inflammation. We hypothesize that specific subsets of monocytes expand with AIDS and drive central nervous system (CNS)
disease. Additionally, there may be expansion of cells from the bone marrow through blood with subsequent macrophage
accumulation in tissues driving pathogenesis. To identify monocytes that recently emigrated from bone marrow, we used 5-
bromo-29-deoxyuridine (BrdU) labeling in a longitudinal study of SIV-infected CD8+ T lymphocyte depleted macaques.
Monocyte expansion and kinetics in blood was assessed and newly migrated monocyte/macrophages were identified
within the CNS. Five animals developed rapid AIDS with differing severity of SIVE. The percentages of BrdU+ monocytes in
these animals increased dramatically, early after infection, peaking at necropsy where the percentage of BrdU+ monocytes
correlated with the severity of SIVE. Early analysis revealed changes in the percentages of BrdU+ monocytes between slow
and rapid progressors as early as 8 days and consistently by 27 days post infection. Soluble CD163 (sCD163) in plasma
correlated with the percentage of BrdU+ monocytes in blood, demonstrating a relationship between monocyte activation
and expansion with disease. BrdU+ monocytes/macrophages were found within perivascular spaces and SIVE lesions. The
majority (80–90%) of the BrdU+ cells were Mac387+ that were not productively infected. There was a minor population of
CD68+BrdU+ cells (,10%), very few of which were infected (,1% of total BrdU+ cells). Our results suggest that an increased
rate of monocyte recruitment from bone marrow into the blood correlates with rapid progression to AIDS, and the
magnitude of BrdU+ monocytes correlates with the severity of SIVE.
Citation: Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, et al. (2010) Increased Monocyte Turnover from Bone Marrow Correlates with Severity of SIV
Encephalitis and CD163 Levels in Plasma. PLoS Pathog 6(4): e1000842. doi:10.1371/journal.ppat.1000842
Editor: Danny C. Douek, NIH/NIAID, United States of America
Received September 1, 2009; Accepted March 3, 2010; Published April 15, 2010
Copyright:  2010 Burdo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grants R01NS40237 (KCW), R01NS37654 (KCW), U19MH081835 (KCW), R01NS06897 (KCW) RR00164 (XA, MJK). The in
vivo CD8 T lymphocyte depletion antibodies used in these studies were provided by the NIH Nonhuman Primate Reagent Resource (RR016001, AI040101). The
funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kenneth.williams.3@bc.edu
Introduction
Monocytes of bone marrow origin are circulating precursors that
give rise to and replenish macrophage populations in tissues,
including the brain [1]. Monocytes that originate from hematopoi-
etic stem cells in bone marrow undergo three stages of
differentiation from monoblasts to promonocytes and then
monocytes where they are released into the circulation [2–4].
Current dogma defines that human and non-human primate
monocytes do not divide out of the bone marrow [5]. Blood
monocytes are thought to circulate in the vasculature for
approximately 24–72 hours before differentiation into macrophag-
es in tissues [2,6]. Continuous extravasation and differentiation of
circulating monocytic precursors has long been considered the sole
source of tissue macrophages [7]. Other mechanisms to maintain
tissue macrophage homeostasis have been identified and described
in rodents including: 1) self-renewal of differentiated resident cells
and 2) homing and limited proliferation of bone marrow derived
precursors in tissues [5,8–11]. Such mechanisms are not thought to
function in humans. Nevertheless, in both rodents and primates in
acute inflammation, monocytes are recruited to tissue compart-
ments [2,12–14]. With acute inflammation, the half-life of
circulating monocytes is decreased coincident with an accumulation
of macrophages at the inflamed site [15,16]. The half-life of
circulating monocytes in chronic inflammation is undefined. Prior
studies of monocyte kinetics used autoradiographic analysis and
radiolabeled thymidine or indium chloride incorporation, which
was powerful but of limited utility due to the toxicity of radiolabel
[6,15–18]. More recently, we and others used the thymidine analog
59-bromo-29-deoxyuridine (BrdU) to quantify the turnover and
release of monocytes from bone marrow [19–24]. BrdU is
incorporated into cellular DNA during replication, at the S-phase
of the cell cycle. Monocytes are released from the bone marrow into
the circulation shortly after the completion of S phase, thus BrdU is
a reliable marker for monocytes newly released into blood [20,21].
We have shown that increased BrdU incorporation in monocytes
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lymph nodes [20]. Increased percentage of BrdU+ monocytes
correlated with AIDS more so than CD4+ T lymphocyte loss or
viral load [20]. In this report, we confirm and extend these
observations in a serial pathogenesis study of monocyte expansion
withemphasis onthe severityof SIVE and identification ofa plasma
marker of monocyte expansion.
Monocytes have been shown to play a critical role in HIV and
SIV disease pathogenesis [25–29]. The expansion of the number
and/or relative percentage of CD14+CD16+ monocytes correlates
with the incidence of HIV encephalitis (HIVE) and accumulation
of monocyte/macrophages in HIVE lesions correlates with
dementia [25,30,31]. Similarly, our laboratory has shown that
SIV-infected CD8+ T lymphocyte depleted rhesus macaques have
a biphasic increase in the percentage and absolute numbers of
CD14+CD16+ monocytes with viremia and later with the
development of AIDS [32–35]. Whether this is from increased
recruitment of monocytes from bone marrow or recirculation from
tissue sources is not defined.
We hypothesized that increased monocyte production from
bone marrow and traffic into the brain during SIV infection
correlates with rapid development of AIDS and severity of SIVE.
To test this, we examined BrdU+ incorporation of monocytes in a
longitudinal serial-sample pathogenesis study using SIV-infected
CD8+ T lymphocyte depleted rhesus monkeys [36–38]. We show
BrdU+ monocytes are negative for the proliferation marker Ki-67,
consistent with monocytes labeled with BrdU in the marrow that
do not proliferate in the blood. We demonstrate a significant
correlation between the increased percentage of BrdU+ monocytes
in blood at necropsy and the severity of SIV disease. Moreover, we
find within CD8+ T lymphocyte depleted animals the magnitude
of BrdU+ monocytes is equal with the rate of disease progression.
We have identified BrdU+ monocyte/macrophages accumulating
in the CNS perivascular space and SIVE lesions. About 80–90%
of BrdU+ cells are Mac387+ that are not productively infected and
likely representative of recently recruited monocyte/macrophages.
A rare population of CD68+ macrophages are BrdU+ and also
productively infected. These results suggest that an increased
number of monocytes emigrating from the bone marrow occurs
with rapid progression to AIDS and correlates with the severity of
SIVE at necropsy. These data further point to the traffic of BrdU+
cells into the CNS. We did not find a correlation between BrdU+
monocytes in blood and plasma LPS levels, but found a correlation
with soluble CD163 (sCD163) levels in plasma, consistent with
monocyte activation and stimulation of innate immunity [39–45].
Overall these data suggest that increased monocyte production
from bone marrow, traffic to the brain, and overall monocyte
activation play major roles in HIV and SIV neuropathogenesis.
Results
In this pathogenesis study, we utilized seven SIVmac251-
infected rhesus macaques that were depleted of CD8+ T
lymphocytes by three injections of a CD8-specific mouse-human
chimeric antibody (cM-T807) at 6, 8 and 12 days post infection.
Of these, one animal was CD8+ T lymphocyte depleted for 21
days (‘‘transiently’’ depleted) and six for greater than 28 days
(‘‘persistently’’ depleted) (Table 1). Animals were sacrificed upon
the development of AIDS (criteria described in Materials and
Methods). This cohort could be subdivided into slow and rapid
progressors. Of the rapid progressors, five animals were sacrificed
with AIDS (56, 75, 77, 89 and 92 days post infection) and four had
SIV encephalitis (SIVE) (criteria described in Materials and
Methods). Of the two slow progressors, one was sacrificed at 131
Author Summary
Human immunodeficiency virus (HIV) and the closely
related simian immunodeficiency virus (SIV) can infect
monocyte/macrophages, which enter and accumulate in
the brain leading to neuronal dysfunction. Monocyte/
macrophages exit the bone marrow, transit through the
blood and enter the central nervous system (CNS). What
triggers these cells to traffic is undefined, but it occurs in
normal non-infected conditions at a rate that is accelerated
with viral infection. Here, we used 5-bromo-29-deoxyur-
idine (BrdU) injection and incorporation into the DNA of
monocytes prior to their departure from the bone marrow.
We found that the percentage of BrdU+ monocytes
leaving the bone marrow 24 hours after injection in-
creased in animals that rapidly succumbed to AIDS and
correlated with the severity of SIV encephalitis (SIVE).
Differences in BrdU labeled monocytes in slow and rapid
progressors were revealed as early as 8 days and were
consistent by 27 days post infection. Soluble CD163, shed
by activated monocyte/macrophages, directly correlated
with BrdU+ monocyte expansion. Our study provides new
insights into the development of HIV-related CNS disease
and underscores the importance of monocyte/macro-
phage recruitment from the bone marrow as an AIDS
defining event.
Table 1. SIV CD8+ T lymphocyte depleted animals used in the study.
ANIMALS CD8+ T LYMPHOCYTE DEPLETION STATUS SURVIVAL (DPI)/GROUP AVG. PLASMA VIRAL LOAD (LOG 10) (SEM) PATHOLOGY
55-05 Persistently depleted 56/Rapid 7.95 (6.94) Mild SIVE
244-96 Persistently depleted 77/Rapid 8.05 (7.63) Severe SIVE
DB79 Persistently depleted 92/Rapid 7.49 (6.83) Severe SIVE
CM07 Persistently depleted 75/Rapid 7.26 (6.75) Mild SIVE
168-05 Persistently depleted 89/Rapid 8.15 (7.08) AIDS noE
288-07 Persistently depleted 131/Slow 8.06 (7.49) AIDS/CMV
186-05 Transiently depleted Alive/Slow 7.69 (7.01) N/A
Animal numbers, CD8 depletion status, length of survival, grouping, average viral load over the course of infection and pathology at time of death are shown in this
table. Persistently depleted is defined by a CD8 T lymphocyte depletion greater than 28 days. Transiently depleted is defined by a length of CD8 T lymphocyte depletion
less than 21 days. DPI=days post infection, SEM=standard error of the mean, Rapid=rapid progressors, Slow=slow progressors, SIVE=SIV encephalitis, AIDS
noE=animal was sacrificed with AIDS, but did not have SIVE, CMV=cytomegalovirus, N/A=not applicable.
doi:10.1371/journal.ppat.1000842.t001
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alive (Table 1).
To examine if the rate of monocyte turnover and traffic into the
brain during SIV infection correlates with disease progression, we
performed serial sample of monocytes 24hrs after BrdU injection
at multiple time points. Flow cytometry on whole blood was used
to identify BrdU+ monocytes with the gating strategy defined in
Figure 1. Monocytes were first identified by FSC versus SSC
profiles, and selection of HLA2DR+ cells with exclusion of CD3+,
CD8+, and CD20+ cells. The percentage of BrdU+ monocytes
was calculated from total monocytes: CD14+CD162,
CD14+CD16+ and CD142CD16+ (excluding CD142CD162
cells) (Figure 1). We have previously shown that monocytes in the
bone marrow were BrdU+Ki-67+ [20]. However, in blood we
found that CD14+ monocytes are BrdU+Ki-672 (Figure 1). These
results are consistent with non-proliferating blood monocytes
labeled with BrdU in bone marrow that lose Ki-67 post-
proliferation (within 24–48 hours), when cells are in the blood
[3,46–49]. The CD142CD162 cells, likely comprised of CD34+
hematopoietic stem cells and dendritic cells (DCs), are BrdU+ and
Ki-67+ (Figure 1). These data are consistent with recent reports
[20,21].
BrdU incorporation in monocytes 24hrs post-BrdU injection in
control, uninfected CD8+ T lymphocyte depleted animals showed
that CD8+ T lymphocyte depletion alone did not affect monocyte
turnover (Figure 2A; n=4). The percentage of BrdU+ monocytes
after CD8+ T lymphocyte depletion was the same as pre-depletion
(approximately 2%). There was no correlation between the
percentage of BrdU+ monocytes and days post CD8+ T
lymphocyte depletion in uninfected animals (r=0.02427,
P=0.9289). There was an increase in BrdU+ monocytes in
CD8+ T lymphocyte-depleted infected (Figure 2B–C) versus
uninfected control animals (Figure 2A) and a higher percentage
of BrdU+ monocytes in rapid (Figure 2C) versus slow progressors
(Figure 2B). Differences in the percentage of BrdU+ monocytes
between animals with rapid versus slow progression were evident
as early as 8 and consistent at 27 days post infection (Figure 2B–C).
No correlation was detected between the percentage of BrdU+
monocytes and days post infection in slow progressors (Figure 2B;
r=20.1464, P=0.7294). In fact, the percentage of BrdU+
monocytes in these animals was similar to non-infected controls.
There was a dramatic increase in the percentage of BrdU+
monocytes in the rapid progressors and a significant correlation
between the percentage of BrdU+ monocytes and days post
infection (Figure 2C; r=0.7651, P=0.0006). At end stage disease,
the percentage of BrdU+ monocytes correlated with the severity of
SIVE (Figure 2C). In rapid progressors, the percentage of BrdU+
cells prior to infection ranged from 0.85%, to 2.77%. This
percentage increased with infection and at necropsy was 6.27% in
an animal with AIDS but no SIVE (AIDS noE), 11.0% in an
animal with mild SIVE, and 23.4% and 31.5% in animals with
severe SIVE (Figure 2C). Thus, the percentage of BrdU+
monocytes correlated with time after infection in rapid progressors
and was increased with severity of SIVE at necropsy (Figure 2C).
To further study if increased monocyte turnover can predict
rapid progression to AIDS, we examined other parameters
previously linked to disease progression including CD4+ T
lymphocyte numbers, CD4+ T lymphocyte turnover, and plasma
Figure 1. Gating strategy for identifying BrdU+ monocytes. In order to identify BrdU+ monocytes after in vivo BrdU injection, we used flow
cytometry on whole blood. We first gated on the monocytes based on their forward (FSC) vs. side scatter (SSC) properties (far left panel), then
excluded HLA-DR negative cells as well as T-lymphocytes using anti-CD3, NK cells using anti-CD8 and B-lymphocytes using anti-CD20 (second panel
from left). Next, we examined monocytes based on their expression of CD14 and CD16 (right top panel). We examined the expression of Ki-67 and
BrdU on monocytes (including CD14+CD162, CD14+CD16+ and CD142CD16+) (bottom right panel). For the purpose of this study, CD142CD162
cells were excluded from all further analyses since this population contains CD34+ hematopoietic stem cells and dendritic cells (bottom left panel).
This gating and data are representative of an infected rapid progressor at day 27 post-infection out of all animals studied.
doi:10.1371/journal.ppat.1000842.g001
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depletion and SIV infection, plasma viral loads peaked by day 8
and remained high throughout the course of disease, consistent
with persistently depleted animals (Table 1) [32,36]. No
correlation was found between percentage of BrdU+ monocytes
and percentage of BrdU+CD4+ T lymphocytes (P=0.2845) or
numbers of CD4+ T lymphocytes (P=0.6641) (Figure 3A and B,
respectively). In addition, there was no correlation between plasma
virus and the percentage of BrdU+ monocytes (P=0.7880) or
percentage of BrdU+CD4+ T lymphocytes (P=0.3701) (Figure 3C
and D, respectively). Because the number of CD4+ T cells increase
with CD8+ lymphocyte depletion, the CD4+ numbers are not
comparable to non-CD8 depleted animals [38].
We examined the kinetics of BrdU+ monocyte subsets
(CD14+CD162 and CD14+CD16+) entering and exiting blood
at four time points: pre-infection (9 days before infection), peak
infection (7 dayspost infection),26 dayspost infection,and either88
days post infection (slow progressors) or 24hrs prior to necropsy
(rapid progressors) (Figure 4A–B and 4C–D). The percentage of
BrdU incorporation was measured at 24hrs and 48hrs and either 96
or 120hrs after a single BrdU injection. First, BrdU incorporation
wasexamined beforeSIVinfection. Inall animals,the percentageof
‘‘classical’’ CD14+CD162 monocytes that were BrdU+ peaked in
blood 48hrs post BrdU (Figure 4A and C; red lines), whereas the
‘‘inflammatory’’ CD14+CD16+ cells that were BrdU+ peaked at
96hrs post BrdU (Figure 4B and D; red lines). This suggests that
CD14+CD16+ cells might arise from CD14+CD162 monocytes in
the blood after leaving the bone marrow or that the majority of the
CD14+CD16+ cells leave the bone marrow later than the
CD14+CD162 cells. Second, the effect of SIV infection on kinetics
of BrdU+ monocyte subsets was examined. In contrast to slow
progressors, a peak in the percentage of BrdU+CD14+CD162
monocytes in rapid progressors appeared at 24hrs post BrdU after
infection (Figure 4C; blue, green, black lines). The percentage of
BrdU+CD14+CD16+ monocytes was increased after infection at
48hrs post BrdU in both slow and rapid progressors (Figures 4B and
D; blue, green, black lines), with a greater increase in the rapid
progressors (Figure 4D). There was no change in any of the
monocyte subsets in the uninfected CD8+ T lymphocyte depleted
animals (data not shown).
Consistent with previous literature describing an increase
of CD14+CD16+ cell numbers in animals with SIVE
[25–27,30,50,51], the absolute number of CD14+CD16+ mono-
cytes was elevated in the rapid progressors (data not shown). There
wasno change inthe absolute numberof CD14+CD16+ monocytes
in the slow progressors throughout infection (data not shown).
Recent studies have shown an association of high plasma LPS
with increased sCD14 thus implicating monocyte activation in
HIV infection [52,53]. Exact correlates between HIV dementia
and plasma LPS were not found [53]. We therefore examined
plasma LPS as a potential stimulus for emigration of monocytes
from the bone marrow. There were no significant differences in
plasma LPS levels between rapid and slow progressors (Figure 5A;
rapid progressors=solid lines, slow progressors=dotted lines) and
no significant correlation between the percentage of BrdU+
monocytes and plasma LPS levels (Figure 5B; r=20.2040,
P=0.5038).
To examine whether increased circulating CCL2/monocyte
chemoattractant protein 1 (MCP-1) can result in enhanced
monocyte emigration from bone marrow, plasma CCL2 levels in
Figure 2. Increased percentage of BrdU+ monocytes is
predictive rapid progression to AIDS and severity of SIVE.
(A–C): BrdU was injected prior to (n=1) and after SIVmac251 infection
(n=3) and the percentages of BrdU+ monocytes 24hrs after BrdU
injection was determined by flow cytometric analysis. A. In four
uninfected CD8+ T lymphocyte depleted animals, the percentage of
BrdU+ monocytes remained approximately 2% of total monocytes in all
time points. Thus, CD8+ T lymphocyte depletion alone without SIV
infection does not alter monocyte turnover (n=4). CD8+ T lymphocyte
depleted SIV infected animals were divided into two groups: slow
progressors (B) and rapid progressors (C). B. Monocyte turnover is
unchanged at all points examined after infection in slow progressors
(n=2). C. The percentages of BrdU+ monocytes increased dramatically
with rapid disease in animals that succumbed to AIDS (n=5). The
magnitude of BrdU+ incorporation of monocytes at necropsy can
differentiate mild and severe SIVE. Each animal is represented by a
different symbol. Error bars are standard error of the mean.
doi:10.1371/journal.ppat.1000842.g002
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levels increased at 9 days post infection and then moderately
decreased in all animals, except one slow progressor whose CCL2
concentration returned to pre-infection levels (Figure 5C; rapid
progressors=solid lines, slow progressors=dotted lines). There
was no correlation between the percentages of BrdU+ monocytes
and plasma CCL2 (Figure 5D; r=0.1049, P=0.7456). Interest-
ingly, sCD163 did correlate with BrdU incorporation, consistent
with activation of monocyte/macrophages and increased mono-
cyte traffic from the bone marrow (Figure 5E and F) [35,39–
42,45,54,55]. In all animals examined, plasma sCD163 levels
increased by 9 days post infection, the time point when slow and
rapid progressors can be distinguished by differences in the
percentage of BrdU+ monocytes (Figure 5E). At day 20, in slow
progressors sCD163 plasma levels decreased (Figure 5E, dotted
lines), but in rapid progressors sCD163 levels continued to increase
(Figure 5E, solid lines). There was a significant correlation between
the percentage of BrdU+ monocytes and plasma sCD163 levels
(Figure 5F; r=0.6391, P=0.02). Thus, sCD163 levels, but not
plasma LPS or CCL2, correlated with the increased percentage of
BrdU+ monocytes in the blood of CD8+ T lymphocyte depleted
SIV-infected macaques.
In a recent study, we showed that higher levels of BrdU+
monocytes in blood were associated with macrophage apoptosis in
lymph nodes [20]. By flow cytometry, we did not find Annexin V+
BrdU+ monocytes suggesting that monocytes were not undergoing
apoptosis in blood (data not shown). Herein, we examined BrdU
labeled cells in the CNS investigating their distribution in the
brains of three animals, two with severe SIVE and one with mild
SIVE (Figure 6). The majority of the BrdU+ cells in all brains were
located within SIVE lesions and in the vasculature (Figure 6A and
B; BrdU: DAB). BrdU+ cells comprised 15.6 and 17.5% of total
cells within SIVE lesions in two rapid progressors with severe
SIVE (Table 2, Figure 6A). In the animal with mild SIVE, similar
percentages of BrdU+ cells were found in lesions, but there were
fewer overall lesions. To determine the identity of the BrdU+ cells,
double immunohistochemistry was performed using antibodies
against CD3 for T cells, GFAP for astrocytes, CD68 for resident
macrophages and Mac387 for recently infiltrated monocyte/
macrophages [56,57]. There was little to no CD3+ T lymphocytes
found in any sections examined (Figure 6C; BrdU: DAB and CD3:
Vector Blue). BrdU+ cells were found in close proximity to
GFAP+ astrocytes, but very few scattered double positive
astrocytes (GFAP+BrdU+) were found (Figure 6D and E; BrdU:
DAB and GFAP: Vector Blue). Approximately 10% of total
BrdU+ cells in SIVE lesions were CD68+ and these BrdU+ cells
comprised between 1.8 and 4.6% of all CD68+ macrophages in
lesions (Figure 6F and G; BrdU: DAB and CD68: Vector Blue and
Figure 3. Percentage of BrdU+ monocytes does not correlate with plasma virus or CD4+ T lymphocyte turnover or numbers. A.
Paired XY values for percentage of BrdU incorporation in CD4+ T lymphocytes and monocytes in all infected animals are plotted. No correlation is
found between the percentage of BrdU+ monocytes and the percentage of BrdU+ CD4+ T lymphocytes (P=0.2379). B. Paired XY values for
percentage of BrdU incorporation monocytes and CD4+ T lymphocyte counts in all seven infected animals are plotted. No correlation is found
between the percentage of BrdU+ monocytes and CD4+ T cell counts (P=6641). C. Paired XY values for percentage of monocyte BrdU incorporation
and plasma viral load in all infected animals are plotted. No correlation is found between the percentage of BrdU+ monocytes and plasma viral loads
P=7880. D. Paired XY values for percentage of BrdU+ CD4+ T cells and plasma virus in all infected animals are plotted. No correlation is found
between the percentage of BrdU+ CD4+ T cells and plasma viral loads P=0.3701. A Spearman rank test is used for statistics.
doi:10.1371/journal.ppat.1000842.g003
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were Mac387+, representing approximately a third of the total
Mac387+ monocyte/macrophages in lesions (Figure 6H and I;
BrdU: Vector Blue and Mac387: DAB and Table 2). The animal
with mild SIVE had similar percentages of BrdU+Mac387+ and
BrdU+CD68+ cells in lesions as the animals with severe SIVE. In
the brains of control non-infected CD8+ T lymphocyte depleted
animals, few scattered BrdU+ macrophages were detected,
representing normal monocyte traffic (data not shown).
Less than 1% of all BrdU+ cells in SIVE lesions were SIVp28+
and less than 0.2% of all SIVp28+ cells were also BrdU+ (Table 2).
Double positive BrdU and SIVp28 cells are very rare events, thus,
resulting in few productively infected BrdU monocyte/macro-
phages. Immunofluorescence confirmed the presence of numerous
BrdU+ cells in blood vessels (Figure 7A), perivascular cuffs
(Figure 7A), and SIVE lesions (Figure 7B–D) and showed that
the majority of the BrdU+ cells were Mac387+ cells (Figure 7C;
BrdU: Vector Blue and Mac387: DAB) that were not productively
infected. Immunofluorescence was used to identify that the
productively SIV infected BrdU+ cells were CD68+ macrophages
(Figure 7A–B and 7D; white arrow). Thus, the majority of the
BrdU+ cells in the brain were Mac387+ that were not productively
infected, representing monocyte/macrophages that were labeled
with BrdU in the bone marrow and had recently trafficked to the
brain (likely from the last two BrdU pulses). These data are
consistent with Mac387 as one of the earliest differentiation
markers expressed on monocyte/macrophages as they enter tissues
[56,57].
Discussion
Here we have presented data showing that increased monocyte
turnover is predictive of rapid development of AIDS. We have
demonstrated that an increased percentage of BrdU+ monocytes
in blood correlated with the severity of SIVE at necropsy.
Interestingly, the differences in the percentage of BrdU+
monocytes were apparent by 8 days post infection and
differentiated between slow and rapid progression by 27 days
post infection. This data lends support to the importance of early
monocyte activation and deregulation in AIDS pathogenesis.
Furthermore, sCD163 levels, but not plasma LPS or CCL2,
correlated with increased percentages of BrdU+ monocytes in the
blood of SIV-infected macaques. In addition, we showed a
differential rate of turnover in two major monocyte populations
(CD14+CD162 and CD14+CD16+) and the acceleration of their
turnover in rapid progressors. BrdU+ cells were detected in the
brains of animals with SIVE; the majority of these cells were
Mac387+ that were SIV p282 and a minor population of CD68+
macrophages, few of which were productively infected. The data
presented here underscore the importance of increased monocyte
turnover and traffic to the brain during SIVE, and emphasize in
this model that CNS lesion formation is an active process requiring
monocyte/macrophage recruitment, likely a result of enhanced
innate immune responses [27,35].
These data confirm and extend the observations recently
reported by Hasegawa and colleagues, who examined BrdU
incorporation in animals at different stages of SIV infection and
Figure 4. Monocyte subsets leave the bone marrow at different rates that are accelerated in animals that develop SIVE. BrdU was
injected four times over the course of the study. Red=pre-infection (days 210 days post infection (dpi)), Blue=peak infection (7 dpi),
Green=‘‘asymptomatic’’ period (26 dpi) and Black=88 dpi (slow progressors=A–B) or necropsy (rapid progressors=C–D). BrdU injections were
given at 24hrs before necropsy. The percentage of BrdU+ monocytes in each subset was determined 24hr and 48hr and either 96 or 120 hrs after
BrdU injection (Time: 0 hr). (A–B) Dots represent the averages of the percentage of BrdU+ cells in the subsets of slow progressors that remained
asymptomatic throughout the period examined. A. There is no change in the percentage of BrdU+ CD14+CD162 cells between pre- and post-
infection time points. B. There is a slight increase in the percentage of BrdU+ CD14+CD16+cells after infection that is apparent at 48hrs. (C–D) Dots
are averages from two rapid progressors (244-96 and 55-05). The percentage of BrdU+ monocytes was only examined 24hrs after BrdU pulse for
animals, DB79 and CM07. C. The difference in the percentage of BrdU+CD14+CD162 cells between pre- and post-infection is apparent at 24hrs. D.
The difference in the percentage of BrdU+ CD14+CD16+cells between pre- and post-infection occurs at 48hrs. The error in all graphs is the standard
error of the mean.
doi:10.1371/journal.ppat.1000842.g004
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acute and chronic infection and a greater expansion with AIDS
[20]. Our results are consistent with that finding, but add the
observation that increased BrdU incorporation in monocytes
correlates with the severity of SIVE and can distinguish between
slow and rapid progressors.
We have presented evidence that increased monocyte traffic
from bone marrow into the circulation correlates with the rapid
progression to AIDS and severity of SIVE. BrdU+ monocytes
traffic from bone marrow through the circulation into the brain,
fostering the development of AIDS and SIVE. An increase in
monocyte traffic in uninfected animals or slow progressors was not
found. These data underscore the important role of monocyte
activation and augmented traffic from the bone marrow to the
brain in SIV neuropathogenesis. Bone marrow diffusion has been
reported to correlate with the incidence of HIV dementia [58].
Additionally, anemia before the onset of AIDS is predictive of
HIV neuropathogenesis [35,58]. It has been demonstrated in SIV
infected monkeys that rapid disease progression is the best
correlate with the development of SIVE [59]. Our data support
these observations and extend these to include that the rate of
monocyte turnover, demonstrated by the percentage of BrdU+
Figure 5. sCD163 levels in plasma, but not LPS or CCL2, correlates with percentage of BrdU+ in total monocytes. A. LPS plasma levels
in the individual SIV infected animals after infection are shown. Solid lines are plasma LPS levels in rapid progressors. Dashed lines are plasma LPS
levels in slow progressors. B. There is no correlation between plasma LPS levels with the percentage of BrdU+ monocytes. C. CCL2/MCP-1 plasma
levels in individual SIV infected animals after infection are shown. The solid lines represent plasma CCL2/MCP-1 levels in rapid progressors. The
dashed lines represent plasma CCL2/MCP-1 levels in slow progressors. D. There is no correlation between plasma CCL2/MCP-1 and the percentage of
BrdU+ monocytes. E. sCD163 plasma levels in individual SIV infected animals after infection are shown. Solid lines are sCD163 plasma in rapid
progressors. Dashed lines are sCD163 plasma in slow progressors. F. There is a significant correlation between sCD163 plasma levels and percentage
of BrdU+ monocytes. The Spearman rank test is used.
doi:10.1371/journal.ppat.1000842.g005
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the severity of SIVE.
The CD8 depletion, SIV infection model produces rapid AIDS
with a high incidence of SIVE by depleting cytotoxic T
lymphocytes. Using this model, there were both slow and rapid
disease progressing animals with varying degrees of severity of
SIVE that correlated with the percentage of BrdU+ monocytes.
However, CD4+ T lymphocytes, which are linked to CD8+ T
lymphocytes, are not regulated in a normal fashion due to
depletion of CD8+ T lymphocytes [38], a possible reason for the
lack of a correlation between CD4+ T lymphocytes with BrdU+
monocytes in our study. However, in a previous report using non-
CD8 depleted SIV infected monkeys, high monocyte turnover also
did not correlate with CD4+T cell number or plasma viral load
[20].
We found that the percentage of BrdU+ monocytes does not
correlate with LPS or CCL2 levels in plasma, but interestingly
sCD163 did; this is consistent with the notion that activation of
monocyte/macrophages and the increase of monocyte traffic from
the bone marrow drive CNS pathogenesis [39,40]. Previous in
vivo and in vitro studies have shown that CD163 expression on
monocytes inversely correlated with sCD163 in plasma or tissue
culture media directly linking sCD163 to monocyte activation
[39,45,55]. In vitro studies show picogram levels of LPS results in
sCD163 release from monocytes, underscoring the role of innate
immune responses in AIDS pathogenesis [45]. In addition, the
level of sCD163 has been shown to increase in association with
macrophage mediated diseases, including sepsis [40] and Gau-
cher’s disease [60], characterized by macrophage accumulation in
the liver and spleen [60]. Thus, increased traffic of monocytes
Figure 6. Histopathologic studies showed evidence of BrdU+ cells, the majority of which are Mac387+, in the brains of macaques
with SIVE. A–B: Immunohistochemistry with an antibody against BrdU is utilized in brain sections of rapid progressors. A: BrdU+ cells are present in
and around SIVE lesions (BrdU: DAB, brown) B: BrdU+ cells are seen in and around the vasculature (BrdU: DAB, brown) C: Immunohistochemistry with
antibodies against CD3 (Vector Blue, blue) and BrdU (DAB, brown) is utilized in brain sections of rapid progressors to examine if BrdU+ cells are CD4+
T lymphocytes. No double label BrdU+ and CD3+ cells are found in the brains of SIVE+ macaques. D and E: Immunohistochemistry with antibodies
against GFAP (Vector Blue, blue) and BrdU (DAB, brown) is utilized in brain sections of rapid progressors to examine if BrdU+ cells are astrocytes.
There are very few BrdU+ astrocytes seen in all sections examined. The arrow points to a BrdU+ in a vessel surrounded by astrocyte foot processes.
The asterisk points out a BrdU+ cells in close proximity to GFAP+ astrocytes. F and G: Immunohistochemistry with antibodies against CD68 (DAB,
brown) and BrdU (Vector Blue, blue) is utilized in brain sections of rapid progressors to examine if BrdU+ cells were CD68+ mature macrophages. Few
BrdU+CD68+ cells are seen. H and I: Double staining with antibodies against BrdU (Vector Blue, blue) and Mac387 (DAB, brown) is utilized to
determine if BrdU+ cells in the brain are early monocyte/macrophage infiltrates. BrdU and Mac387 did co-localization in the brain of SIVE animals. The
arrows indicate BrdU+Mac387+ monocyte/macrophages, in a lesion (H) or perivascular region (I). The asterisk is a Mac387 BrdU- cell in the
vasculature. Brain sections are representative of three SIVE+ animals examined for all stains.
doi:10.1371/journal.ppat.1000842.g006
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circulation) and increased levels of sCD163 in the plasma are
consistent with an inflammatory environment resulting from
stimulation of innate immunity that may play important roles in
the development of SIVE.
Release of monocytes from the bone marrow could be triggered
by increased apoptosis of monocytes in the blood. Although
CD3+CD4+ T cells from HIV-1 subjects have been shown to
undergoconstitutiveandinducedapoptosis[61],HIV-1+monocytes
are resistant [61]. Recently, it was demonstrated that peripheral
blood monocytesfrom chronically HIV-1 infected individualshave a
stable anti-apoptotic gene signature suggesting a greater resistance to
apoptosis incirculating monocytesduring HIV infection [61]. In this
study, pro-apoptotic genes were down-regulated and anti-apoptotic
genes were up-regulated in infected monocytes [61]. When we
examined whole blood by flow cytometry for the presence of
apoptotic monocytes, we did not detect monocytes that were
Annexin V and propidium iodide (PI) positive 24hrs after BrdU
injection (data not shown). Thus, we could rule out apoptosis of
peripheral blood monocytes as a trigger for the increased release of
monocytes from the bone marrow. Apoptosis of tissue macrophages
in lymph nodes has already been demonstrated to correlate with the
percentage of BrdU monocyte label in blood [20].
A report by Serbina and Pamer suggested that monocyte
emigration from bone marrow during bacterial infection requires
signals mediated by the chemokine receptor CCR2 [62]. Using a
Ccr22/2 mouse model, it was found that CCR2 is important for
release of Ly6C
hi monocytes (equivalent to the CD14+CD162
monocytes in humans) from bone marrow [62]. A more recent
paper concluded that not only CCL2, but also CCL7 (MCP-3) was
critical in monocyte mobilization from the bone marrow [63]. We
did not see a correlation between CCL2 plasma levels and the
percentage of BrdU+ monocytes, but that does not rule out the
involvement of CCR2 and additional ligands. In addition, the
chemokine CXCL12 (SDF-1) and its receptor CXCR4 are known
to be involved in the retention of hematopoietic stem cells in the
bone marrow [64,65]. The roles of these additional factors are
worthy of exploration in the SIV model of disease and may lead to
further insight into the increased release of monocytes from the
bone marrow during AIDS and SIVE progression.
Not only did we find differences in the percent of BrdU+ total
monocytes between slow and rapid progressors, but we found
kinetic differences in BrdU incorporation of two monocyte subsets,
CD14+CD162 and CD14+CD16+ entering the blood from the
bone marrow. In the rapid progressors, the percentage of BrdU
incorporation was increased dramatically with infection in both
populations. The CD14+CD162 (CCR2+) monocyte population
may have accelerated release due to increased levels of MCP-3, as
discussed above. The CD14+CD16+ monocyte blood population
has been shown to be phenotypically similar to perivascular
macrophages in the brain, which supports the concept that the
CD14+CD16+ monocytes transmigrate into the brain to differ-
entiate further into perivascular macrophages [25,33]. Our data
suggests that although CD14+CD16+ cells leave the bone marrow
later than CD14+CD162 cells, the CD14+CD16+ cells spend less
time in the circulation, possibly a result of traffic to tissues. This
likelihood is supported by the finding that CD14+CD16+
monocytes are inflammatory mediators expressing high levels of
pro-inflammatory cytokines and are potent antigen presenting
cells. We have not ruled out the possibility that CD14+CD162
monocytes convert to CD14+CD16+ monocytes in blood [66].
The overall number of brain macrophages in HIVE and SIVE
is increased despite evidence of proliferation in situ, supported by
the notion that the majority of these macrophages are derived
from the periphery [25,34]. Here, we present evidence that newly
infiltrated BrdU+ monocyte/macrophages are a significant
population of monocyte/macrophages in perivascular cuffs and
lesions in brains of SIVE+ animals. Recruited monocytes may
increase the number of viral target cells in the brain. Most of the
BrdU+ cells were Mac387+ cells representing newly recruited and
infiltrated monocytes/macrophages [56,57]. It is not known how
long the BrdU+Mac387+ cells stay in the CNS with lesion
formation nor at which BrdU pulse these cells were labeled in the
periphery. This might, in part, explain why CD68+BrdU+ cells
are found in the CNS; they might have trafficked earlier as less
mature cells and undergone maturation within tissues. Addition-
ally, the CD68+ BrdU+ cells could have migrated directly from
the blood, thus bringing HIV into the CNS. Lastly, they may
represent macrophages that divided in the CNS, although we
believe this in unlikely since we found little evidence of BrdU+
microglia, astrocytes or epithelial cells in our studies. We have
previously shown using specific markers for cell proliferation,
including Ki-67 and topoisomerase II alpha, that macrophages
within SIVE lesions were not undergoing significant active
proliferation in the time frame studied [34].
Increased monocyte turnover correlated with high levels of
sCD163 in plasma. These findings along with potential anti-
inflammatory properties of sCD163 [44], which is directly shed
from the M2 anti-inflammatory alternative activated macrophages
[39,67], suggest that BrdU+ cells recruited to the CNS may aid in
Table 2. Percentages of BrdU+, Mac387+, CD68+ and
SIVp28+ cells in SIVE lesions.
Animal 244-96 Animal DB79
BrdU+ cells vs. all cells
# 15.661.5; n=34 17.561.7; n=19
BrdU+Mac387+ cells vs. all BrdU+ cells* 81.067.8; n=14 92.264.7; n=11
BrdU+CD68+ cells vs. all BrdU+ cells** 9.863.0; n=31 10.767.6; n=5
BrdU+SIVp28+ cells vs. all BrdU+ cells*** 0.7860.39; n=27 0.4860.48; n=14
BrdU+Mac387+ cells vs. all Mac387+ cells
{ 34.064.9; n=14 45.368.3; n=11
BrdU+CD68+ cells vs. all CD68+ cells
{{ 1.860.5; n=31 4.663.9; n=5
BrdU+SIVp28+ cells vs. all SIVp28+ cells
{{{ 0.1260.062; n=27 0.1960.19; n=14
#Mean6SEM (standard error of the mean) of the percentage of BrdU+ cells in
SIVE lesions calculated as followed; (number of BrdU+ cells/total number of
cells in lesions using hematoxylin) 6100.
*Mean6SEM of the percentage of BrdU+ cells expressing Mac387 in SIVE lesions
calculated as followed; (number of BrdU+Mac387+ cells/total number of BrdU+
cells) 6100.
**Mean6SEM of the percentage of BrdU+ cells expressing CD68 in SIVE lesions
calculated as followed; (number of BrdU+CD68+ cells/total number of BrdU+
cells) 6100.
***Mean6SEM of the percentage of BrdU+ cells expressing SIVp28 in SIVE
lesions calculated as followed; (number of BrdU+SIVp28+ cells/total number of
BrdU+ cells) 6100.
{Mean6SEM of the percentage of Mac387+ cells expressing BrdU in SIVE lesions
calculated as followed; (number of BrdU+Mac387+ cells/total number of
Mac387+ cells) 6100.
{{Mean6SEM of the percentage of CD68+ cells expressing BrdU in SIVE lesions
calculated as followed; (number of BrdU+CD68+ cells/total number of CD68+
cells) 6100.
{{{Mean6SEM of the percentage of SIVp28+ cells expressing BrdU in SIVE
lesions calculated as followed; (number of BrdU+SIVp28+ cells/total number
of SIVp28+ cells) 6100.
n=number of total lesions examined. For 244-96 frontal cortex, prefrontal
cortex and basal nuclei and for DB79 frontal cortex and occipital cortex sections
were examined. The mild SIVE animal, 55-05, had similar percentages of BrdU+
cells, BrdU+Mac387+ and BrdU+CD68+ cells in lesions compared to DB79 and
244-96, but there were fewer lesions overall.
doi:10.1371/journal.ppat.1000842.t002
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as inflammatory cells in response to or causing neuronal injury or
as anti-inflammatory vehicles to minimize injury to the brain
during SIV infection.
Although we detected very few SIVp28+ BrdU+ cells in SIVE
brains, this does not rule out the possibility that the BrdU+ cells
are not latently infected. In fact, our data suggests BrdU+ cells
may act as viral reservoirs that may with maturation actively
replicate virus. Our finding that only the BrdU+CD68+
monocytes are productively infected underscores the importance
of monocyte/macrophage maturation (possibly Mac387 to CD68
expression) for active viral replication. Invasion of the CNS by
BrdU+Mac387+ perivascular macrophages with concomitant viral
infection of the CNS compartment upon maturation is a likely
scenario for this. Overall, our data examining BrdU+ monocytes
in blood and BrdU+ monocyte/macrophages with the brain,
underscore the role of monocyte/macrophages derived from bone
marrow in AIDS pathogenesis and CNS disease.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the Harvard University’s Institutional
Animal Care and Use Committee, and all animal work was
approved by this committee.
Animals, viral infection and CD8+ T lymphocyte
depletion
Eleven rhesus macaques were utilized in this study. Seven
animals were infected with SIVmac251 (20 ng of SIV p27) by
intravenous injection, kindly provided by Ronald Desrosiers. In
order to achieve rapid disease progression with high incidence of
SIVE, animals were CD8+ T lymphocyte depleted by treatment
with a human anti-CD8 antibody cM-T807 administered s.c.
(10mg/kg) at 6 days post infection and i.v. (5mg/kg) at 8 and 12
days post infection (previously described [32]). Four uninfected
Figure 7. The majority of BrdU+ monocyte/macrophages in the brain are not productively infected. Triple label with antibodies against
BrdU (red), SIV p28 (green), CD68 (blue) is used to determine if BrdU+ cells are productively infected. Side panels are single-color images of SIVp28
(green), BrdU (red), CD68 (blue) and differential interference contrast (DIC). A: BrdU+ (red) cells in blood vessels and a BrdU+ cell infiltrated in the
brain B–D: Multiple BrdU+ cells are detected in and around SIVE lesion. B: BrdU+ cells are seen in and around this SIVE lesion; the majority BrdU+ cells
are SIV p282 and thus not productively infected. C: The majority of the BrdU+ cells in lesions are Mac387+. Double label with antibodies against BrdU
(blue) and Mac387 (brown) in an SIVE lesion is shown. D: An SIVE lesion in the brain of a rapid progressor showing a rare triple positive cell: SIV-
infected CD68+BrdU+ macrophage (white arrow). Data presented here are representative of n=3 macaques with SIVE. Multiple tissue sections from
different brain regions were examined.
doi:10.1371/journal.ppat.1000842.g007
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depleted by treatment with a human anti-CD8 antibody cM-T807
administered once (50mg/kg) i.v. and two were CD8+ T
lymphocyte depleted by treatment with a rhesus anti-CD8
antibody cM-T807 administered once (50mg/kg) i.v. These
antibodies were provided by the NIH Non-human Primate
Reagent Resource (RR016001, AI040101). CD8+ T lymphocyte
depletion was monitored by flow cytometry prior to antibody
treatment and weekly thereafter during infection (as previously
described [32]). All animals were housed at Harvard University’s
New England Regional Primate Research Center in accordance
with standards of the American Association for Accreditation of
Laboratory Animal Care. Animals were anesthetized with
ketamine-HCl and euthanized by an intravenous pentobarbital
overdose and exsanguinated. Animals were sacrificed with any of
the following 5 criteria: 1. weight loss .15% body weight in 2
weeks or .30% body weight in 2 months, 2. documented
opportunistic infection, 3. persistent anorexia .3 days without
explicable cause, 4. severe intractable diarrhea, progressive
neurological signs or 5. significant cardiac and/or pulmonary
signs. The diagnosis of AIDS was determined by the presence of
AIDS defining lesions: Pneumocystis pneumonia, Mycobacterium
avium infection (most commonly small intestine, liver and
mesenteric lymph node), intestinal adenovirus infection (most
common in small intestine). Other, less common lesions include
SIV giant cell disease in the lung, gut, and lymph nodes and SIV
associated arteriopathy. SIV encephalitis (SIVE) was defined by
the presence of multinucleated giant cells (MNGC) and accumu-
lation of macrophages, some of which are infected [59,68–70]. No
animals with opportunistic infections in the CNS were used in this
study.
Viral load determination
Plasma SIV RNA was quantified using real-time PCR as
previously described [71]. SIV virions were pelleted from 0.5ml
EDTA plasma by centrifugation at 20,000 g for 1 hour. The
fluorescently labeled, real-time PCR probe employed contained a
non-fluorescent quencher, BHQ-1, at its 39 end. The threshold
sensitivity was 100 copy Eq/ml, with an average interassay
coefficient of variation of less than 25%.
BrdU administration
A 30 mg/ml stock of solution was prepared by adding 5-bromo-
29-deoxyuridine (BrdU) (Sigma) to 16 PBS (without Ca
2+ and
Mg
2+), U.S.P. grade (Aestus Pharmaceuticals) and heated to 60uC
in water bath (as previously described [20,24]). BrdU was
administered as a slow bolus i.v. injection at a dose of 60 mg
BrdU/kg body weight. In the uninfected animals, BrdU was given
four times throughout the study (days 211, 3, 38 and 72 days post-
CD8 antibody administration). In the infected animals, BrdU was
administered pre-infection (day 29), peak infection (day 7), and
days 26, day 50 (n=1) and 88 (n=2) post infection and 24 hours
prior to necropsy (n=4; days 55, 76, 88 and 91). CM07 did not
receive BrdU prior to necropsy.
Flow cytometry
Flow cytometric analyses were performed with 100 ml aliquots
of EDTA-coagulated whole blood. Erythrocytes were lysed using
ImmunoPrep Reagent System (Beckman Coulter), washed twice
with PBS containing 2% FBS, then incubated for 15 minutes at
room temperature with fluorochrome-conjugated surface antibod-
ies including anti-HLA-DR-PerCp-Cy5.5 (clone L243), anti-
CD16-PE-Cy7 (clone 3G8; BD Biosciences), anti-CD3-APC (clone
SP34-2), anti-CD8-APC (clone RPA-T8;), anti-CD20-APC (clone
2H7) and anti-CD14-Pacific blue (clone M5E2) (BD Biosciences).
For intracellular staining, cells were fixed and permeabilized with
BD Cytofix/Cytoperm
TM buffer (BD Biosciences) for 30 mins at
room temperature. Cells were again washed and incubated with
BD Cytoperm Plus
TM buffer for 10 mins on ice, then washed and
incubated with DNase (30mg) for 1hr at 37uC, washed and then
stained for intracellular antigen with anti-BrdU-FITC (clone 3D4;
BD Biosciences) and anti-Ki-67-PE (clone B56; BD Biosciences)
for 20 mins at room temperature. For controls, BrdU naı ¨ve
animals and isotype controls were used. To test for apoptotic
monocytes anti-Annexin V (Invitrogen) and propidium iodine (PI;
BD Biosciences) were used. Samples were acquired on a BD FACS
Aria (BD Biosciences) and analyzed with Tree Star Flow Jo version
8.7.
sCD163 and CCL2 ELISAs and LAL assay
Soluble CD163 (sCD163) and CCL2 plasma levels were
quantified by ELISA according to manufacturer’s protocol
(Trillium Diagnostics and R&D Systems, respectively). The
Diazo-coupled Limulus amebocyte lysate (LAL) assay (Associates
of Cape Cod Inc.) was used to quantify endotoxin/liposaccharide
(LPS) levels in plasma from SIV-infected animals, according to the
manufacturer’s protocol. Briefly, samples diluted 1/5 were
inactivated for 30 min at 65uC and incubated with LAL for
30 min at 37uC. Addition of reagents led to formation of a
magenta derivative that absorbs light at 570 nm. For LAL assay,
samples were handled with non-pyrogenic plastic or glassware to
avoid LPS contamination.
Immunohistochemistry
Formalin-fixed, paraffin-embedded brain tissues were depar-
affinized and assessed by immunohistochemistry for BrdU (Mouse
IgG1; Dako, 1:50, 1hr room temperature. Before primary
antibody incubation, non-serum protein block was applied. The
EnVision+ System- horseradish peroxidase (HRP) (EnVision+ Kit;
DAKO) was used according to the manufacturers’ instructions.
The color reaction product was developed using 3,39-diamino-
benzidine tetrahydrochloride (DAB; DAKO) as the chromogenic
substrate for HRP. The sections were counterstained with
hematoxylin and then dehydrated and mounted. Controls
consisted of the addition of isotype-matched immunoglobulin.
To detect BrdU
+ cells and CD3+ T lymphocytes, GFAP+
astrocytes, SIVp28+ infected cells, CD68+ macrophages and
Mac387+ monocyte/macrophages in monkey brains, double-label
immunohistochemistry was performed using the DAKO Double
Stain System, according to the manufacturer’s instructions. The
color reaction product was developed using DAB and Vector Blue
(Vector Laboratories). Sections were visualized under a Zeiss Axio
Imager M1 microscope (Carl Zeiss MicroImaging, Inc., Thorn-
wood, NY) using Plan-Apochromat 620/0.8 and 640/0.95 Korr
objectives.
Confocal microscopy
Tissues were collected in 10% neutral buffered formalin, and
embedded in paraffin. Tissues were sectioned at 6 mm and
deparaffinized with xylene and hydrated in graded alcohols.
Immunohistochemical staining followed a basic protocol using a
citrate antigen retrieval method. For immunofluorescence, sections
were blocked with 10% normal goat serum (NGS) in PBS with
0.2% Fish Skin Gelatin (FSG) (Sigma) for 40 min. Tissues were
incubated with rat anti-BrdU (IgG2a; BU1/75, Novus Biologicals,
1:50, 1hr RT) followed by AlexaFluor 568 conjugated goat anti-rat
IgG (Molecular Probes; 1:500), then with mouse anti-SIV p28
(IgG1; Microbix Biosystems, 1:500) followed by AlexaFluor 488
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then CD68-biotin conjugated (1:20, overnight at 4uC) followed by
streptavidin conjugated AlexaFluor 568 (Molecular Probes; 1:500).
After immunofluorescence labeling and washing, sections were
treated with 50 mmol/L CuSO4 ammonium buffer for 45 min-
utes to quench auto-fluorescence. Confocal microscopy was
performed using a Leica TCS SP2 laser-scanning microscope
equipped with 3 lasers (Leica Microsystems, Exton, PA).
Individual optical slices represent 0.2 mm. Optical slices were
collected at 5126512 pixel resolution. The fluorescence of
individual fluorochromes was captured separately in a sequential
mode, after optimization to reduce bleed-through between
channels (photomultiplier tubes) using Leica software. NIH Image
v1.62 and Adobe Photoshop v7 software were used to assign
correct colors of up to four channels collected (3 fluorochromes:
Alexa 488 (green), Cy3, Alexa 568 (red), and Alexa 647 (far red),
and the differential interference contrast image (gray scale).
Statistical analysis
For statistical analyses we used the Prism version 5.0a
(GraphPad Software, Inc., San Diego, CA) software. Spearman
rank test was used for all correlations.
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